“Vemurafenib (PLX4032, Zelboraf®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance” (2013) Journal of Cancer Research Updates, 2(4), pp.  306–317. doi:10.6000/1929-2279.2013.02.04.9.